WellSpring Consumer Healthcare, a leading provider of trusted OTC and personal care solutions, recently announced the strategic acquisition of DerMend and Recticare (“Ferndale Brands”) from Ferndale Pharma Group, further expanding its leadership in therapeutic skincare. Financial terms of the transaction were not disclosed. WellSpring Consumer Healthcare is a portfolio company of Avista Healthcare Partners (“Avista”), a leading middle-market healthcare private equity firm with 20 years of experience in building growth-oriented healthcare businesses.
DerMend and Recticare are established brands with strong brand equity and offer a differentiated and professionally endorsed portfolio within Therapeutic Skincare. DerMend provides dermatologist-recommended topical creams for aging, fragile, or bruised skin, while Recticare offers fast-acting topical relief for hemorrhoids. Products for the Ferndale Brands are distributed through leading brick-and-mortar retailers and e-commerce channels.
Chris Brown, CEO of WellSpring, said: “The addition of the Ferndale Brands represents a significant step in strengthening WellSpring’s portfolio of trusted OTC and personal care solutions. These brands align seamlessly with our commitment to deliver high-quality products that meet consumers’ evolving health and wellness needs.”
The acquisition of the Ferndale Brands represents WellSpring’s third add-on acquisition since Avista’s initial investment in August 2022, following a portfolio acquisition of A+D and Solarcaine from Bayer AG in April 2023 and the acquisition of vH essentials from Wisconsin Pharmacal Company in July 2024.
Read Similar News:
XRP Healthcare Upgrades its Digital Health App
Tecsys launches TecsysIQ to unlock AI-powered insights in healthcare supply chain
